Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(08): 554-560
DOI: 10.1055/a-1734-2466
Article

The ISAQ Score Does Not Predict Adrenal Crisis in Patients with Primary Adrenal Insufficiency

Marcus Quinkler 
1   Endocrinology in Charlottenburg, Berlin, Germany
,
Tina Kienitz
1   Endocrinology in Charlottenburg, Berlin, Germany
› Author Affiliations Funding This study did not receive any funding.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI).

Design This was a prospective single-centre study over three years.

Methods Patients answered the ISAQ at baseline and were seen every 4–6 months in the endocrine outpatient clinic. At each visit previous infectious periods which required an increase in daily glucocorticoid dosage and AC were reported and documented. Seventy-five patients with PAI (53 women; 43 patients with autoimmune PAI, 20 patients with salt-wasting congenital adrenal hyperplasia and 12 patients who underwent bilateral adrenalectomy) were analysed. Due to the COVID-19 pandemic and consecutive lockdown measures, the data were analysed separately for March 2018 to March 2020 (period 1), and March 2020 to March 2021 (period 2).

Results During period 1 the ISAQ score significantly correlated with the number of reported infectious events (r=0.351; p<0.01), but not during period 2 (r=0.059, p=0.613), in which the number of infectious events per patient-year significantly decreased (1.1±0.1 vs 0.4±0.1; p<0.001). The frequency of AC decreased from 8.8 to 2.4 per 100 patient-years between the two study periods. The ISAQ score was not different between patients with or without AC.

Conclusions The ISAQ score does not identify patients prone to ACs. The COVID-19 pandemic and consecutive lockdown measures significantly diminished the frequency of infectious events and ACs.

Key words

Addison’s disease - ISAQ score - AddiQoL - adrenal crisis - COVID-19 - congenital adrenal hyperplasia


Publication History

Received: 29 October 2021
Received: 12 December 2021

Accepted: 04 January 2022

Article published online:
03 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hahner S, Loeffler M, Fassnacht M. et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92: 3912-3922
    CrossrefPubMedGoogle Scholar
  • 2 Bergthorsdottir R, Leonsson-Zachrisson M, Oden A. et al. Premature mortality in patients with Addison’s disease: A population-based study. J Clin Endocrinol Metab 2006; 91: 4849-4853
    CrossrefPubMedGoogle Scholar
  • 3 Erichsen MM, Lovas K, Skinningsrud B. Wolff ABet al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: Observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94: 4882-4890
    CrossrefPubMedGoogle Scholar
  • 4 Bornstein SR, Allolio B, Arlt W. et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2016; 101: 364-389
    Google Scholar
  • 5 Hahner S, Ross RJ, Arlt W. et al. Adrenal insufficiency. Nat Rev Dis Primers 2021; 7: 19
    CrossrefPubMedGoogle Scholar
  • 6 Hahner S, Loeffler M, Bleicken B. et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. Eur J Endocrinol 2010; 162: 597-602
    CrossrefPubMedGoogle Scholar
  • 7 Smans LC, Van der Valk ES, Hermus AR. et al. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2016; 84: 17-22
    CrossrefPubMedGoogle Scholar
  • 8 Meyer G, Neumann K, Badenhoop K. et al. Increasing prevalence of Addison’s disease in German females: Health insurance data 2008-2012. Eur J Endocrinol 2014; 170: 367-373
    CrossrefPubMedGoogle Scholar
  • 9 Meyer G, Badenhoop K, Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2 5-fold risk for adrenal crises: German health insurance data 2010-2013. Clin Endocrinol (Oxf) 2016; 85: 347-353
    CrossrefPubMedGoogle Scholar
  • 10 Reisch N, Willige M, Kohn D. et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 35-42
    CrossrefPubMedGoogle Scholar
  • 11 Hahner S, Spinnler C, Fassnacht M. et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: A prospective study. J Clin Endocrinol Metab 2015; 100: 407-416
    CrossrefPubMedGoogle Scholar
  • 12 Quinkler M, Murray RD, Zhang P. et al. Characterization of patients with adrenal insufficiency and frequent adrenal crises. Eur J Endocrinol 2021; 184: 761-771
    CrossrefPubMedGoogle Scholar
  • 13 White K, Arlt W. Adrenal crisis in treated Addison’s disease: A predictable but under-managed event. Eur J Endocrinol 2010; 162: 115-120
    CrossrefPubMedGoogle Scholar
  • 14 Ono Y, Ono S, Yasunaga H. et al. Clinical features and practice patterns of treatment for adrenal crisis: A nationwide cross-sectional study in Japan. Eur J Endocrinol 2017; 176: 329-337
    CrossrefPubMedGoogle Scholar
  • 15 Smans LC, Souverein PC, Leufkens HG. et al. Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: A cohort study. Eur J Endocrinol 2013; 168: 609-614
    CrossrefPubMedGoogle Scholar
  • 16 Peter H-H, Goldacker S, Haraldseide J. et al. Construction and clinical validation of a questionnaire-based risk score to identify patients suffering from immunodeficiency or systemic autoimmunity. British Journal of Medicine & Medical Research 2014; 4(29): 4751-4769
    CrossrefPubMedGoogle Scholar
  • 17 Isidori AM, Venneri MA, Graziadio C. et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 173-185
    CrossrefPubMedGoogle Scholar
  • 18 Reincke M, Ritzel K, Oßwald A. et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing’s syndrome. Eur J Endocrinol 2015; 173: M23-M32
    CrossrefPubMedGoogle Scholar
  • 19 Ali SR, Bryce J, Haghpanahan H. et al. Real-world estimates of adrenal insufficiency-related adverse events in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2021; 106: e192-e203
    CrossrefPubMedGoogle Scholar
  • 20 Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 2015; 172: R115-R124
    CrossrefPubMedGoogle Scholar
  • 21 Castell S, Akmatov MK, Obi N. et al. Test-retest reliability of an infectious disease questionnaire and evaluation of self-assessed vulnerability to infections: Findings of Pretest 2 of the German National Cohort. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 1300-1307
    CrossrefPubMedGoogle Scholar
  • 22 Sievers C, Akmatov MK, Kreienbrock L. et al. Evaluation of a questionnaire to assess selected infectious diseases and their risk factors: Findings of a multicenter study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 1283-1291
    CrossrefPubMedGoogle Scholar
  • 23 Løvås K, Curran S, Oksnes M. et al. Development of a disease-specific quality of life questionnaire in Addison’s disease. J Clin Endocrinol Metab 2010; 95: 545-551
    CrossrefPubMedGoogle Scholar
  • 24 Øksnes M, Bensing S, Hulting AL. et al. Quality of life in European patients with Addison’s disease: Validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 2012; 97: 568-576
    CrossrefPubMedGoogle Scholar
  • 25 Bratland E, Skinningsrud B, Undlien DE. et al. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 5117-5124
    CrossrefPubMedGoogle Scholar
  • 26 Koniaris LG, Wand G, Wright TM. TNF mediates a murine model of Addison’s crisis. Shock 2001; 15: 29-34
    CrossrefPubMedGoogle Scholar
  • 27 Bancos I, Hazeldine J, Chortis V. et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality. Eur J Endocrinol 2017; 176: 471-480
    CrossrefPubMedGoogle Scholar
  • 28 Robert Koch-Institut. Surveillance of Influenza in Germany Season 2020/2021. https://influenza.rki.de/Diagrams.aspx?agiRegion=0
    PubMed
  • 29 Paul-Ehrlich Institut. Cumulative Number of Released Doses of Infleunza Vaccines in Germany. https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/vorsaisons/influenza-saisonal-2020-2021-inhalt.htmljsessionid=74C6C95E208A35EA47575974DBDB2E37.intranet211?nn=175430
    PubMed
  • 30 Flaxman S, Mishra S, Gandy A. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257-261
    CrossrefPubMedGoogle Scholar
  • 31 Zhang R, Li Y, Zhang AL. et al. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci U S A 2020; 117: 14857-14863
    CrossrefPubMedGoogle Scholar
  • 32 Carosi G, Morelli V, Del Sindaco G. et al. Adrenal insufficiency at the time of COVID-19: A retrospective study in patients referring to a tertiary center. J Clin Endocrinol Metab 2021; 106: e1354-e1361
    CrossrefPubMedGoogle Scholar
  • 33 Castinetti F, Amodru V, Brue T. Adrenal crisis may occur even in patients with asymptomatic COVID-19. Endocr Pract 2020; 26: 929-930
    CrossrefPubMedGoogle Scholar
  • 34 Martino M, Aboud N, Cola MF. et al. Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: The CORTI-COVID study. J Endocrinol Invest 2021; 44: 1075-1084
    CrossrefPubMedGoogle Scholar
  • 35 Arlt W, Baldeweg SE, Pearce SHS. et al. Endocrinology in the time of COVID-19: Management of adrenal insufficiency. Eur J Endocrinol 2020; 183: G25-G32
    CrossrefPubMedGoogle Scholar
  • 36 Tresoldi AS, Sumilo D, Perrins M. et al. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2020; 105: 418-429
    CrossrefPubMedGoogle Scholar
  • 37 Quinkler M, Ekman B, Marelli C. et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect 2017; 6: 1-8
    CrossrefPubMedGoogle Scholar
  • 38 Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth. Pediatrics 2000; 106: 767-773
    CrossrefPubMedGoogle Scholar